" class="no-js "lang="en-US"> Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older - Pharmtech Focus
Wednesday, February 01, 2023

Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the European Medicines Agency (EMA) has authorized a third dose of the Moderna COVID-19 vaccine (Spikevax) given at least 28 days after the second dose to severely immunocompromised individuals 12 years of age or older.

“We recognize the need to protect immunocompromised individuals who are at the highest risk of severe COVID-19 disease. It is promising to see recent trials demonstrating that a third dose of the Moderna COVID-19 vaccine may enhance immune response in this important population,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We remain committed to helping to end the COVID-19 pandemic with our mRNA vaccine.”

A growing number of studies have shown the benefit of a third dose of COVID-19 vaccine in immunocompromised subjects. In particular, a recent double-blind, randomized controlled trial of 120 individuals who had undergone solid organ transplant procedures (heart, kidney, kidney-pancreas, liver, lung, pancreas) demonstrated that a third dose of the Moderna COVID-19 vaccine improved immune response compared to placebo1. In the study, the third dose was generally well tolerated.

People In This Post

Companies In This Post

  1. Sherlock Biosciences Acquires Sense Biodetection Advancing CRISPR-Based Diagnostics for Consumers Read more
  2. Genoscience Pharma receives FDA Orphan Drug Designation for ezurpimtrostat to treat HepatoCellular Carcinoma (HCC) Read more
  3. AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors Read more
  4. Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myeloid Leukaemia Read more
  5. Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, as Chief Medical Officer Read more